Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 33 | 2024 | 1346 | 3.060 |
Why?
|
| Heart-Assist Devices | 31 | 2024 | 866 | 2.950 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 121 | 1.300 |
Why?
|
| Hemodynamics | 14 | 2023 | 756 | 1.260 |
Why?
|
| Heart Transplantation | 7 | 2023 | 774 | 0.810 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 638 | 0.780 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 402 | 0.670 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2023 | 143 | 0.650 |
Why?
|
| Palliative Care | 1 | 2020 | 263 | 0.600 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 376 | 0.510 |
Why?
|
| Rare Diseases | 1 | 2016 | 71 | 0.510 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2021 | 151 | 0.450 |
Why?
|
| Heart Ventricles | 6 | 2023 | 795 | 0.400 |
Why?
|
| Cardiac Catheterization | 5 | 2020 | 324 | 0.380 |
Why?
|
| Cardiac Output | 4 | 2022 | 159 | 0.380 |
Why?
|
| Middle Aged | 32 | 2024 | 27030 | 0.330 |
Why?
|
| Echocardiography, Doppler | 3 | 2019 | 193 | 0.330 |
Why?
|
| Thrombosis | 3 | 2020 | 312 | 0.310 |
Why?
|
| Tricuspid Valve | 2 | 2020 | 107 | 0.310 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 54 | 0.300 |
Why?
|
| Thromboembolism | 2 | 2019 | 126 | 0.300 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2020 | 244 | 0.300 |
Why?
|
| Humans | 44 | 2024 | 92337 | 0.300 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 130 | 0.290 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 123 | 0.290 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 97 | 0.290 |
Why?
|
| Retrospective Studies | 18 | 2023 | 9703 | 0.290 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2020 | 190 | 0.280 |
Why?
|
| Device Removal | 2 | 2019 | 163 | 0.280 |
Why?
|
| Male | 32 | 2024 | 43925 | 0.260 |
Why?
|
| Female | 31 | 2024 | 47893 | 0.240 |
Why?
|
| Aged | 20 | 2024 | 19943 | 0.240 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 133 | 0.230 |
Why?
|
| Galectin 3 | 1 | 2024 | 20 | 0.230 |
Why?
|
| Echocardiography | 5 | 2020 | 968 | 0.220 |
Why?
|
| Ventricular Function, Right | 3 | 2020 | 152 | 0.220 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2022 | 83 | 0.210 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 27 | 0.210 |
Why?
|
| Cannula | 2 | 2020 | 56 | 0.200 |
Why?
|
| Arterial Pressure | 2 | 2020 | 40 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2022 | 58 | 0.180 |
Why?
|
| Incidence | 4 | 2021 | 1661 | 0.180 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 330 | 0.180 |
Why?
|
| Aortic Valve | 2 | 2021 | 260 | 0.180 |
Why?
|
| Complement C4b | 1 | 2021 | 33 | 0.180 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 98 | 0.180 |
Why?
|
| Lactic Acid | 1 | 2021 | 99 | 0.170 |
Why?
|
| Prospective Studies | 8 | 2020 | 4468 | 0.170 |
Why?
|
| Sex Factors | 1 | 2023 | 1095 | 0.170 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 28 | 0.170 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 19 | 0.170 |
Why?
|
| Aminobutyrates | 1 | 2019 | 13 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 24 | 0.160 |
Why?
|
| Heart | 2 | 2023 | 584 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 81 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 124 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.160 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 30 | 0.160 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.160 |
Why?
|
| Vasodilation | 1 | 2019 | 93 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2020 | 110 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2024 | 8740 | 0.160 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 199 | 0.160 |
Why?
|
| Stroke Volume | 2 | 2019 | 499 | 0.160 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 8 | 0.150 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 106 | 0.150 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.150 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2020 | 254 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 273 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 167 | 0.140 |
Why?
|
| Thermodilution | 1 | 2017 | 20 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2018 | 195 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2019 | 377 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 291 | 0.130 |
Why?
|
| Prognosis | 5 | 2024 | 3872 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 5430 | 0.130 |
Why?
|
| Graft Rejection | 2 | 2021 | 1110 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 148 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 3775 | 0.120 |
Why?
|
| Global Health | 1 | 2016 | 199 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2019 | 393 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2022 | 2458 | 0.110 |
Why?
|
| Stroke | 2 | 2020 | 1038 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 927 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 760 | 0.100 |
Why?
|
| Prevalence | 1 | 2016 | 1294 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1744 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 694 | 0.090 |
Why?
|
| Lung | 1 | 2018 | 1337 | 0.090 |
Why?
|
| Risk Factors | 5 | 2020 | 5704 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 2369 | 0.080 |
Why?
|
| Exercise Test | 2 | 2021 | 171 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2022 | 2978 | 0.080 |
Why?
|
| Adult | 8 | 2020 | 27532 | 0.080 |
Why?
|
| Illinois | 2 | 2019 | 503 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2019 | 443 | 0.060 |
Why?
|
| Galectins | 1 | 2024 | 11 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1763 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 149 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1919 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 75 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 200 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 165 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2021 | 168 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 323 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 291 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2021 | 251 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 30 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 56 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Valsartan | 1 | 2019 | 11 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 24 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 41 | 0.040 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 12 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 61 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 94 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 76 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 206 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 55 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 206 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2021 | 465 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 185 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 115 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2018 | 123 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 302 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2018 | 134 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 287 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 197 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2019 | 303 | 0.040 |
Why?
|
| Neutropenia | 1 | 2018 | 217 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1850 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 376 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1194 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 317 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2019 | 264 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 661 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1807 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 165 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 689 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 871 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 800 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 987 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1902 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2009 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1503 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2729 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7348 | 0.020 |
Why?
|